OraSure Technologies, Inc. (OSUR)
After hours:
| Previous Close | 4.7000 |
| Open | 4.7200 |
| Bid | 4.7200 x 300 |
| Ask | 4.7500 x 600 |
| Day's Range | 4.6700 - 4.7700 |
| 52 Week Range | 4.3800 - 8.4500 |
| Volume | |
| Avg. Volume | 919,888 |
| Market Cap | 349.827M |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | 15.77 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
OraSure Reports Q1 ’24 Revenue of $54.1 Million
Q1 GAAP EPS of $(0.05); Q1 Non-GAAP EPS of $0.04 Restructuring initiatives expected to result in $15 million of annualized expense reductions once fully implemented and position OraSure to achieve cash flow breakeven for core business by end of 2024 Delivered initial orders for Syphilis Health Check™ as part of our distribution agreement with Diagnostics Direct BETHLEHEM, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnosti
- GlobeNewswire
OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th
BETHLEHEM, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2024 financial results and certain business developments for 4:45 p.m. ET on Wednesday, May 8, 2024. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration
- GlobeNewswire
OraSure Reports Q4 ‘23 Revenue of $75.9 Million
Q4 GAAP EPS of $0.27; Q4 Non-GAAP EPS of $0.22 Grew cash balance to $290.4 million as of December 31, 2023 Enters U.S. Syphilis testing market via strategic distribution agreement with Diagnostics Direct BETHLEHEM, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services, today announced its financial results for the three months ended Decem
